Invivoscribe Marketing, Author at Invivoscribe

PRODUCTS
- Products Overview
  Invivoscribe provides a full range of standardized CE-marked in vitro diagnostic cGMP products for hematology-oncology, as well as RUO assays, analyte specific reagents (ASRs), and DNA & RNA controls.
  
  EXPLORE PRODUCTS ⟶
  SEARCH PRODUCT DOCUMENTS & IFUs ⟶
- Next-Generation Sequencing
  CE-IVD
  Illumina®
  Thermo Fisher®
  RUO
  Illumina®
  Thermo Fisher®
  MRD Clonality
  FLT3 ITD MRD
- Companion Diagnostics (CDx)
  LeukoStrat® CDx FLT3
  Mutation Assay
  CE-IVD
  IVD (US)
  IVD (JP)
- ABI Fluorescence Detection
  CE-IVD
  Clonality
  FLT3
  RUO
  Clonality
  FLT3
  Translocations
- Gel Detection
  CE-IVD
  Clonality
  FLT3
  Translocations
  RUO
  Clonality
  FLT3
  Translocations
- Controls
  Master Mix Controls
  DNA Controls
  RNA Controls
  MRD Controls
- Reagents
  ASRs
  Enzymes
  Hi-Di Formamide
- 2022 Product Catalog
CLINICAL LAB SERVICES
- Clinical Lab Services Overview
  The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.
  EXPLORE SERVICES ⟶
- Companion Diagnostic (CDx) Tests
  CDx – USA
  CDx – Germany
  CDx – Japan
- NGS Cancer Panels
  MyAML
  MyMRD
- MFC Panels
  Hematolymphoid Screening Panel
  AML MRD Assay
- MRD NGS Tests
  Clonality
  FLT3 ITD
  NPM1
- Clonality NGS Tests
  SHM
  IGH
  IGK
  TRG
  TRB
DISEASES
- Lymphoid
  Mature B-cell
  Mature T-cell
  
  Lymphoma
  Lymphoma is a cancer that starts in cells that are part of the body’s immune system. Knowing which type of lymphoma you have is important because it affects your treatment options and your outlook (prognosis).
  
  LEARN MORE ⟶
- Myeloid
  Myelodysplastic Syndromes (MDS)
  Acute Myeloid Leukemia (AML)
  Myeloproliferative Neoplasms (MPNs)
  
  Myeloma
  Multiple myeloma is a cancer of plasma cells. Normal plasma cells are found in the bone marrow and are an important part of the immune system.
  
  LEARN MORE ⟶
- Hematological Testing Menu
  Browse our comprehensive menu of product & testing services.
  EXPLORE MENU ⟶
PARTNERSHIPS
- Partnerships Overview
  A proven strategy to accelerate drug approvals
  EXPLORE PARTNERSHIPS ⟶
- Product Development
  Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays
  EXPLORE ⟶
- Manufacturing
  cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents
  EXPLORE ⟶
- LabPMM®
  Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment
  EXPLORE ⟶
- Global Regulatory Expertise
  Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)
  EXPLORE ⟶
SCIENCE
- Science Overview
  We take pride in expanding the science that bridges personalized medicine with quality healthcare.
  EXPLORE OUR SCIENCE ⟶
- Personalized Medicine
  Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.
  EXPLORE PERSONALIZED MEDICINE ⟶
PUBLICATIONS
- Featured Publication
  November 17th, 2020
  Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing
  VIEW PUBLICATION ⟶
- Latest Publications
  April 20th, 2021
  Validation of a Next-Generation Sequencing-based T-Cell Receptor Gamma Gene Rearrangement Diagnostic Assay: Transitioning from Capillary Electrophoresis to Next-Generation Sequencing
  VIEW PUBLICATION ⟶
  November 17th, 2020
  Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing
  VIEW PUBLICATION ⟶
  VIEW ALL PUBLICATIONS ⟶
COMPANY
- Company
  About Us
  Leadership Team
  Board of Directors
  Newsroom
  Global Distributors
  Licensure and Certifications
  Search Career Openings
  Shop Corporate Gear
- Invivoscribe Locations
  
  Invivoscribe, Inc. (USA)
  San Diego, CA, US
  CONTACT US ⟶
  
  Invivoscribe, SARL (France)
  Marseille, France
  CONTACT US ⟶
  
  Invivoscribe Diagnostic Technologies,(Shanghai) Co.,Ltd.
  Shanghai, China
  CONTACT US ⟶
- Clinical Lab Locations
  
  LabPMM, LLC (USA)
  San Diego, CA, US
  CONTACT US ⟶
  
  LabPMM, GmbH (Germany)
  Munich, Germany
  CONTACT US ⟶
  
  LabPMM, GK (Japan)
  Kawasaki, Japan
  CONTACT US ⟶
  
  Invivoscribe Diagnostic Technologies,(Shanghai) Co.,Ltd.
  Shanghai, China
  CONTACT US ⟶
- Support
  
  Invivoscribe, Inc. (USA)
  CONTACT US ⟶
  
  Invivoscribe, SARL (France)
  CONTACT US ⟶
  
  Invivoscribe Diagnostic Technologies,(Shanghai) Co.,Ltd.
  CONTACT US ⟶
  
  LabPMM, LLC (USA)
  CONTACT US ⟶
  
  LabPMM, GmbH (Germany)
  CONTACT US ⟶
  
  LabPMM, GK (Japan)
  CONTACT US ⟶
Search
- Search Articles & Publications
  Search for:
- Search Products & Services
  SEARCH ⟶
- Search Product Documents & IFUs
  SEARCH ⟶

About Invivoscribe Marketing

This author has not yet filled in any details.
So far Invivoscribe Marketing has created 123 blog entries.

Lab Secrets: The Potential for NGS-based MRD Testing for Acute Lymphoblastic Leukemia – The Austin Experience

Invivoscribe Marketing2022-11-18T23:16:58+00:00November 15th, 2022|2022 Videos, 2022 Webinars, Featured Videos, Videos|

Kronos Bio and Invivoscribe Partner on Companion Diagnostic for Use with Entospletinib, Kronos Bio’s Investigational Compound Being Developed for Patients with AML

Invivoscribe Marketing2022-08-16T20:08:13+00:00August 16th, 2022|2022 Press Releases, Press Releases|

A Comprehensive Solution for AML Precision Diagnostics

Invivoscribe Marketing2022-08-02T14:52:04+00:00July 20th, 2022|2022 Videos, 2022 Webinars, Featured Videos, Videos|

Next-generation sequencing of immunoglobulin genes in lymphoid malignancies

Invivoscribe Marketing2022-05-25T03:00:57+00:00May 19th, 2022|2022 Videos, Featured Videos, Videos|

Real-world data on prognostic value of measurable residual disease assessment by fragment analysis or next-generation sequencing in multiple myeloma

Invivoscribe Marketing2022-09-07T22:22:23+00:00May 3rd, 2022|2022 Publications, Featured Publications, Publications|

Corporate Overview

Invivoscribe Marketing2022-05-25T03:00:57+00:00March 10th, 2022|2022 Videos, Featured Videos, Videos|

Lab Secrets: Stratification and Prognoses of Leukemia and Multiple Myeloma using Next-Generation Sequencing (NGS)

Invivoscribe Marketing2022-05-25T03:00:57+00:00February 24th, 2022|2022 Videos, Featured Videos, Videos|

Review of Guidelines for Interpreting Somatic Hypermutation Status in Chronic Lymphocytic Leukemia in the Era of High-Throughput Sequencing

Invivoscribe Marketing2022-05-25T03:00:57+00:00January 26th, 2022|2022 Videos, Featured Videos, Videos|

ASH 2022

Invivoscribe Marketing2022-04-15T00:09:01+00:00December 10th, 2021|Conferences|

Global Standardization of Flow Cytometry Results with AI Systems

Invivoscribe Marketing2022-05-25T03:00:57+00:00December 8th, 2021|2021 Videos, 2021 Webinars, Featured Videos, Videos, Webinars|

AMP 2022

Invivoscribe Marketing2022-04-15T00:08:46+00:00November 2nd, 2021|Conferences|

Explore the Benefits, Considerations, and Utility of NGS B- and T-cell Clonality

Invivoscribe Marketing2022-05-25T03:00:57+00:00October 28th, 2021|2021 Videos, 2021 Webinars, Featured Videos, Videos, Webinars|

JSH 2022

Invivoscribe Marketing2022-04-15T00:07:22+00:00October 14th, 2021|Conferences|

JCA 2022

Invivoscribe Marketing2022-04-15T00:07:34+00:00September 29th, 2021|Conferences|

SOHO 2022

Invivoscribe Marketing2022-04-15T00:06:42+00:00September 28th, 2021|Conferences|

EAHP-SH 2022

Invivoscribe Marketing2022-04-15T00:09:30+00:00September 17th, 2021|Conferences|

Blood 2022

Invivoscribe Marketing2022-04-15T00:09:16+00:00September 11th, 2021|Conferences|

AGBT 2022

Invivoscribe Marketing2022-04-15T00:06:53+00:00September 8th, 2021|Conferences|

Roswell Park Comprehensive Cancer Center Licenses Invivoscribe’s LymphoTrack Software for Plug and Play Pipeline Use

Invivoscribe Marketing2021-09-02T16:53:40+00:00September 2nd, 2021|2021 Press Releases, Press Releases|

Critical Mistakes to Avoid when Developing a Drug/CDx Combination for International Registrations

Invivoscribe Marketing2022-05-25T03:00:58+00:00August 24th, 2021|2021 Videos, Featured Videos, Videos|

JSLH 2022

Invivoscribe Marketing2022-04-15T00:07:10+00:00July 30th, 2021|Conferences|

Invivoscribe Announces Key Submission in the EU, Expanded Presence and Activity in China

Invivoscribe Marketing2021-07-22T17:27:56+00:00July 22nd, 2021|2021 Press Releases, Press Releases|

A Streamlined Laboratory Workflow for Controlling Antibody and Reagent Lots on a 12C Flow Cytometry System

Invivoscribe Marketing2022-05-25T03:00:58+00:00July 15th, 2021|2021 Videos, 2021 Webinars, Featured Videos, Videos, Webinars|

Japanese Association of Molecular Target Therapy of Cancer 2022

Invivoscribe Marketing2022-04-15T00:09:44+00:00June 29th, 2021|Conferences|

PMWC 2022

Invivoscribe Marketing2022-04-15T00:07:46+00:00June 28th, 2021|Conferences|

Title